Skip to main content
HCG · Health Care · 2026-08-21

Healthcare Global Enterprises Ltd

7.0★★ GoodStrong +6.1Stage 2 · wk 5In scan: Pullback Hunter · Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹726
-0.62% today
₹10,839 Cr · Mid cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.

Visit company website →
P/E (TTM)
673.4
Forward 46.1
Earnings Growth (YoY)
-71.2%
Revenue +11.5%
ROE
+1.9%
Profit margin +0.5%
vs 52W High
-6.5%
₹521.8 lo₹776.3 hi
6.5% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 5
1w13w26w
Week 5 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
13.5%
200 DMA: ₹639.5 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.45x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 trending up · +4.5% vs MA50 +3.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #53 of 84 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Ranks #8 of 15 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 33w
S2 56w
S2 22w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 33w → S3 4w → S2 2w → S3 8w → S1 1w → S4 3w → S1 1w → S2 56w → S3 4w → S2 22w → S3 6w → S4 12w → S1 10w → S2 4w current
Total tracked: 167 weeks across 15 stage runs.
1M
+8.4%
3M
+11.0%
6M
+24.2%
YTD
+8.1%
1Y
+6.5%
Scan Membership
Pullback Hunter
Latest: 2026-08-21
Prop Scan
Latest: 2026-08-21
Breakout Watch
Latest: 2026-07-24
26 appearances in last 60 days. First seen: 2024-02-26.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 5 · Vol x
2026-08-20S2
Wk 4 · Vol x
2026-08-19S2
Wk 4 · Vol x
2026-08-18S2
Wk 4 · Vol x
2026-08-17S2
Wk 4 · Vol x
2026-08-14S2
Wk 4 · Vol x
2026-08-13S2
Wk 3 · Vol x
2026-08-12S2
Wk 3 · Vol x
2026-08-11S2
Wk 3 · Vol x
2026-08-10S2
Wk 3 · Vol x
2026-08-07S2
Wk 3 · Vol x
2026-08-06S2
Wk 2 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹664.6
200 DMA
₹639.5
52W High
₹776.3
52W Low
₹521.8
5D Low
₹712.4
Resistance levels (recent highs)
20d High
₹745.3
60d High
₹745.3
120d High
₹745.3
250d High
₹776.3
Next resistance
+2.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.